Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.

Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP, Corey L, Mullins JI, McElrath MJ, Gilbert P.

PLoS One. 2012;7(8):e43396. doi: 10.1371/journal.pone.0043396. Epub 2012 Aug 27.

PMID:
22952672
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

PMID:
21857901
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.

Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, McElrath MJ, Shiver JW, Casimiro DR, Corey L, Self SG.

PLoS One. 2011;6(6):e20479. doi: 10.1371/journal.pone.0020479. Epub 2011 Jun 10.

PMID:
21695251
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.

Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, DiNubile MJ, Quirk E; Merck V526-001 Study Group.

Clin Vaccine Immunol. 2009 Sep;16(9):1285-92. doi: 10.1128/CVI.00144-09. Epub 2009 Jul 15.

PMID:
19605598
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Nef-specific CD8+ T cell responses contribute to HIV-1 immune control.

Adland E, Carlson JM, Paioni P, Kløverpris H, Shapiro R, Ogwu A, Riddell L, Luzzi G, Chen F, Balachandran T, Heckerman D, Stryhn A, Edwards A, Ndung'u T, Walker BD, Buus S, Goulder P, Matthews PC.

PLoS One. 2013 Sep 2;8(9):e73117. doi: 10.1371/journal.pone.0073117. eCollection 2013.

PMID:
24023819
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load.

Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team.

J Virol. 2004 Apr;78(7):3233-43.

PMID:
15016844
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.

Gray G, Buchbinder S, Duerr A.

Curr Opin HIV AIDS. 2010 Sep;5(5):357-61. doi: 10.1097/COH.0b013e32833d2d2b. Review.

PMID:
20978374
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik K, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study Team.

PLoS One. 2012;7(3):e34134. doi: 10.1371/journal.pone.0034134. Epub 2012 Mar 30.

PMID:
22479542
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
[PubMed - indexed for MEDLINE]
10.

Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.

Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, Lederman MM, Carrington M, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study Team.

J Infect Dis. 2011 Apr 1;203(7):976-83. doi: 10.1093/infdis/jiq143. Erratum in: J Infect Dis. 2011 Aug;204(4):664.

PMID:
21402549
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, O'Sullivan A, Crossler J, Jones T, Nau M, Wong K, Zhao H, Raugi DN, Sorensen S, Stoddard JN, Maust BS, Deng W, Hural J, Dubey S, Michael NL, Shiver J, Corey L, Li F, Self SG, Kim J, Buchbinder S, Casimiro DR, Robertson MN, Duerr A, McElrath MJ, McCutchan FE, Mullins JI.

Nat Med. 2011 Mar;17(3):366-71. doi: 10.1038/nm.2316. Epub 2011 Feb 27.

PMID:
21358627
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.

Fellay J, Frahm N, Shianna KV, Cirulli ET, Casimiro DR, Robertson MN, Haynes BF, Geraghty DE, McElrath MJ, Goldstein DB; National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Immunology; NIAID HIV Vaccine Trials Network.

J Infect Dis. 2011 Mar 15;203(6):773-9. doi: 10.1093/infdis/jiq125. Epub 2011 Jan 28.

PMID:
21278214
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.

Payne RP, Kløverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, Sims S, Hickling S, Riddell L, Chen F, Luzzi G, Edwards A, Phillips R, Prado JG, Goulder PJ.

J Virol. 2010 Oct;84(20):10543-57. doi: 10.1128/JVI.00793-10. Epub 2010 Aug 4.

PMID:
20686036
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.

Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, Casimiro DR, Carrington M, Geraghty DE, Gilbert PB, McElrath MJ, Frahm N.

J Infect Dis. 2013 Oct 15;208(8):1231-9. doi: 10.1093/infdis/jit322. Epub 2013 Jul 21.

PMID:
23878319
[PubMed - indexed for MEDLINE]
15.

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group.

Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.

PMID:
18433307
[PubMed - indexed for MEDLINE]
Free Article
16.

Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.

Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA.

J Virol. 2002 Mar;76(5):2298-305.

PMID:
11836408
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.

Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI.

Vaccine. 2012 Jun 22;30(30):4465-75. doi: 10.1016/j.vaccine.2012.04.082. Epub 2012 May 6.

PMID:
22569124
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.

PMID:
19012954
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.

Horton H, Havenar-Daughton C, Lee D, Moore E, Cao J, McNevin J, Andrus T, Zhu H, Rubin A, Zhu T, Celum C, McElrath MJ.

J Virol. 2006 Oct;80(19):9779-88.

PMID:
16973582
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.

Pettersen FO, Taskén K, Kvale D.

Clin Exp Immunol. 2010 Aug;161(2):315-23. doi: 10.1111/j.1365-2249.2010.04179.x. Epub 2010 May 10.

PMID:
20491784
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk